Spectral AI Inc (MDAI) Q1 2025 Earnings Call Highlights: Strong Financial Performance and ...

GuruFocus News

Wed, May 14, 2025, 12:20 AM 4 min read

• Research and Development Revenue: Increased by 6% to $6.7 cardinal from $6.3 cardinal successful Q1 2024.

• Gross Margin: Improved to 47.2% from 46.6% successful Q1 2024.

• General and Administrative Expenses: Reduced to $4.1 cardinal from $5.1 cardinal successful Q1 2024.

• Operating Loss: Decreased to $896,000 from a nett nonaccomplishment of $2.1 cardinal successful Q1 2024.

• Net Income: Reported astatine $2.9 cardinal compared to a nett nonaccomplishment of $3.2 cardinal successful Q1 2024.

• Cash and Cash Equivalents: Totaled $14.1 cardinal arsenic of March 31, 2025, up from $5.2 cardinal connected December 31, 2024.

• Shares Outstanding: 25,588,121 shares arsenic of March 31, 2025.

• Revenue Guidance for 2025: Approximately $21.5 million, excluding imaginable income from the UK and Australia.

• Warning! GuruFocus has detected 2 Warning Signs with MDAI.

Release Date: May 13, 2025

For the implicit transcript of the net call, delight notation to the full net telephone transcript.

• Spectral AI Inc (NASDAQ:MDAI) reported a beardown commencement to 2025 with important accomplishments successful merchandise advancement and operating efficiencies.

• The institution is connected way for its FDA de novo classification submission by the extremity of the 2nd 4th of 2025.

• The pain validation survey results demonstrated the superior show of the DeepView technology, which volition enactment the FDA submission.

• Spectral AI Inc (NASDAQ:MDAI) successfully completed a indebtedness financing statement with Avenue Capital, securing up to $15 cardinal successful funding.

• Research and improvement gross for the archetypal 4th roseate 6% to $6.7 million, reflecting accrued enactment nether the BARDA Project BioShield contract.

• The institution anticipates little gross from the BARDA declaration successful the 2nd fractional of the twelvemonth arsenic it focuses connected further developments of the DeepView system.

• General and administrative expenses, though reduced, inactive correspond a important cost, with a absorption connected operational efficiencies needed to support a agelong currency runway.

• The FDA submission process involves known and chartless risks, and the result is not guaranteed contempt efforts to de-risk the submission.

• The commercialization of the DeepView strategy extracurricular the BARDA situation is inactive successful aboriginal stages, with efforts needed to grow beyond the archetypal contract.

• The improvement of the DeepView SnapShot M for subject usage is ongoing, with nary warrant of gathering the 2027 timeline for availability.

Q: On the guidance, you're calling for $21.5 cardinal conscionable from BARDA revenue. You're tracking up of that, truthful immoderate propulsion guardant determination successful presumption of what you saw successful the archetypal quarter? A: Vincent Capone, CFO: We had a beardown commencement to the year, reflecting our absorption connected the FDA submission by the extremity of the 2nd quarter. The 2nd fractional of the twelvemonth whitethorn spot little gross from the BARDA declaration arsenic we enactment connected further developments of the DeepView system. We are assured successful the $21.5 cardinal gross guidance, but whitethorn restate it if we proceed to outperform.